214 related articles for article (PubMed ID: 30679330)
1. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
2. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
3. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
Cruickshank MN; Ford J; Cheung LC; Heng J; Singh S; Wells J; Failes TW; Arndt GM; Smithers N; Prinjha RK; Anderson D; Carter KW; Gout AM; Lassmann T; O'Reilly J; Cole CH; Kotecha RS; Kees UR
Leukemia; 2017 Jan; 31(1):40-50. PubMed ID: 27443263
[TBL] [Abstract][Full Text] [Related]
4. A pediatric case of
Murphy L; Siegele B; Carstens B; Hartman L; Faulk K
Leuk Lymphoma; 2024 Jun; 65(6):843-847. PubMed ID: 38372299
[No Abstract] [Full Text] [Related]
5. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in
Fournier E; Inchiappa L; Delattre C; Pignon JM; Danicourt F; Bemba M; Roche-Lestienne C; Daudignon A; Decool G; Roumier C; Dumezy F; Fournier L; Grardel N; Preudhomme C; Duployez N
Leuk Lymphoma; 2019 Jul; 60(7):1827-1830. PubMed ID: 30616415
[No Abstract] [Full Text] [Related]
9. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
10. miR-101 suppresses the development of
Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
[No Abstract] [Full Text] [Related]
11. B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Kemps PG; Cleven AHG; van Wezel T; van Eijk R; Bot FJ; Veelken H; van Balen P; Kerkhoffs JH
Am J Hematol; 2020 Nov; 95(11):1427-1429. PubMed ID: 32243611
[No Abstract] [Full Text] [Related]
12. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
13. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
14. The role of constitutive activation of FMS-related tyrosine kinase-3 and
Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
[No Abstract] [Full Text] [Related]
15. Extramedullary relapse of
Aldoss I; Song JY
Blood; 2018 May; 131(22):2507. PubMed ID: 29853461
[No Abstract] [Full Text] [Related]
16. Congenital acute myeloid leukaemia with KMT2A rearrangement.
Wan Ariffin E; Jones H; Bhatnagar N
Br J Haematol; 2018 Jul; 182(2):169. PubMed ID: 29797490
[No Abstract] [Full Text] [Related]
17. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
18. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
19. MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.
Stam RW; Hubeek I; den Boer ML; Buijs-Gladdines JG; Creutzig U; Kaspers GJ; Pieters R
Leukemia; 2006 Jan; 20(1):179-82. PubMed ID: 16307022
[No Abstract] [Full Text] [Related]
20. Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
Permikin Z; Popov A; Verzhbitskaya T; Riger T; Plekhanova O; Makarova O; Froňková E; Trka J; Meyer C; Marschalek R; Tsaur G; Fechina L
Leuk Res; 2022 Jan; 112():106758. PubMed ID: 34864370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
